⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151544 | 1.00 | — | — | |
| SCHEMBL12535915 | 1.00 | — | — | |
| SCHEMBL896133 | 1.00 | — | — | |
| SCHEMBL43516 | 1.00 | — | — | |
| SCHEMBL10151561 | 1.00 | — | — | |
| SCHEMBL735480 | 1.00 | — | — | |
| SCHEMBL896134 | 1.00 | — | — | |
| SCHEMBL12439901 | 1.00 | — | — | |
| SCHEMBL24744320 | 0.97 | THRB (0.53) | — | |
| SCHEMBL21251132 | 0.97 | THRB (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | claimed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | claimed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | claimed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | claimed |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| EP-4245756-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11701354-B2 | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| EP-1438052-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL&minus;INOSITOL 3&minus;KINASE DELTA | ICOS CORPORATION (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6667300-B2 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003035075-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1278748-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | disclosed |
| WO-2001081346-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |